Association between hsa-miR-34b/c rs4938723 T > C promoter polymorphism and cancer risk: A meta-analysis based on 6,036 cases and 6,204 controls

Chinese Journal of Cancer Research

Volumn 26, Issue 3, 2014, Pages 315-322

  Tao, Tao ^a   Chen, Shuqiu ^a   Xu, Bin ^a   Liu, Chunhui ^a   Wang, Yiduo ^a   Huang, Yeqing ^a   Chen, Ming ^a  

^a SOUTHEAST UNIVERSITY   (China)

Author keywords

Cancer; Hsa miR 34b c; Meta analysis; Polymorphism

Indexed keywords

BIOLOGICAL MARKER; HSA MIR 34B C; MICRORNA; PRI MIR 34B C; PROTEIN P53; UNCLASSIFIED DRUG;

ARTICLE; CANCER RISK; CARCINOGENESIS; CASE CONTROL STUDY; COLORECTAL CANCER; DISEASE ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; LIVER CELL CARCINOMA; META ANALYSIS; ONCOGENE; PROMOTER REGION; SENSITIVITY ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW; TUMOR SUPPRESSOR GENE;

EID: 84903889958     PISSN: 10009604     EISSN: 19930631     Source Type: Journal    
DOI: 10.3978/j.issn.1000-9604.2014.06.18     Document Type: Article

References (27)

1. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-97.
2. Ambros V. The functions of animal microRNAs. Nature 2004;431:350-5.
3. Gong J, Zhang JP, Li B, et al. MicroRNA-125b promotes apoptosis by regulating the expression of Mcl-1, Bcl-w and IL-6R. Oncogene 2013;32:3071-9.
4. Krek A, Grün D, Poy MN, et al. Combinatorial microRNA target predictions. Nat Genet 2005;37:495-500.
5. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 2004;5:522-31. (Pubitemid 38868508)
6. Mocellin S, Pasquali S, Pilati P. Oncomirs: from tumor biology to molecularly targeted anticancer strategies. Mini Rev Med Chem 2009;9:70-80.
7. Johnnidis JB, Harris MH, Wheeler RT, et al. Regulation of progenitor cell proliferation and granulocyte function by microRNA-223. Nature 2008;451:1125-9. (Pubitemid 351317447)
8. Aumiller V, Förstemann K. Roles of microRNAs beyond development - metabolism and neural plasticity. Biochim Biophys Acta 2008;1779:692-6.
9. He L, He X, Lim LP, et al. A microRNA component of the p53 tumour suppressor network. Nature 2007;447:1130-4. (Pubitemid 47014436)
10. Hermeking H. p53 enters the microRNA world. Cancer Cell 2007;12:414-8. (Pubitemid 350046413)
11. Bommer GT, Gerin I, Feng Y, et al. p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol 2007;17:1298-307. (Pubitemid 47176893)
12. Majid S, Dar AA, Saini S, et al. miRNA-34b inhibits prostate cancer through demethylation, active chromatin modifications, and AKT pathways. Clin Cancer Res 2013;19:73-84.
13. Gao LB, Li LJ, Pan XM, et al. A genetic variant in the promoter region of miR-34b/c is associated with a reduced risk of colorectal cancer. Biol Chem 2013;394:415-20.
14. Xu Y, Liu L, Liu J, et al. A potentially functional polymorphism in the promoter region of miR-34b/c is associated with an increased risk for primary hepatocellular carcinoma. Int J Cancer 2011;128:412-7.
15. Han Y, Pu R, Han X, et al. Associations of pri-miR- 34b/c and pre-miR-196a2 polymorphisms and their multiplicative interactions with hepatitis B virus mutations with hepatocellular carcinoma risk. PLoS One 2013;8:e58564.
16. Li L, Wu J, Sima X, et al. Interactions of miR-34b/c and TP-53 polymorphisms on the risk of nasopharyngeal carcinoma. Tumour Biol 2013;34:1919-23.
17. Zhang S, Qian J, Cao Q, et al. A potentially functional polymorphism in the promoter region of miR-34b/ c is associated with renal cell cancer risk in a Chinese population. Mutagenesis 2014;29:149-54.
18. Oh J, Kim JW, Lee BE, et al. Polymorphisms of the pri- miR-34b/c promoter and TP53 codon 72 are associated with risk of colorectal cancer. Oncol Rep 2014;31:995-1002.
19. Son MS, Jang MJ, Jeon YJ, et al. Promoter polymorphisms of pri-miR-34b/c are associated with hepatocellular carcinoma. Gene 2013;524:156-60.
20. Bensen JT, Tse CK, Nyante SJ, et al. Association of germline microRNA SNPs in pre-miRNA flanking region and breast cancer risk and survival: the Carolina Breast Cancer Study. Cancer Causes Control 2013;24:1099-109.
21. Yin J, Wang X, Zheng L, et al. Hsa-miR-34b/c rs4938723 T>C and hsa-miR-423 rs6505162 C>A polymorphisms are associated with the risk of esophageal cancer in a Chinese population. PLoS One 2013;8:e80570.
22. Tao T, Wang Y, Luo H, et al. Involvement of FOS-mediated miR-181b/miR-21 signalling in the progression of malignant gliomas. Eur J Cancer 2013;49:3055-63.
23. Yang H, Dinney CP, Ye Y, et al. Evaluation of genetic variants in microRNA-related genes and risk of bladder cancer. Cancer Res 2008;68:2530-7. (Pubitemid 351521830)
24. Carlquist JF, Horne BD, Mower C, et al. An evaluation of nine genetic variants related to metabolism and mechanism of action of warfarin as applied to stable dose prediction. J Thromb Thrombolysis 2010;30:358-64.
25. Ye Y, Wang KK, Gu J, et al. Genetic variations in microRNA-related genes are novel susceptibility loci for esophageal cancer risk. Cancer Prev Res (Phila) 2008;1:460-9.
26. Gao LB, Bai P, Pan XM, et al. The association between two polymorphisms in pre-miRNAs and breast cancer risk: a meta-analysis. Breast Cancer Res Treat 2011;125:571-4.
27. Vogt M, Munding J, Grüner M, et al. Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas. Virchows Arch 2011;458:313-22.